30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Saccades were measured by magnetic search coil technique in 13 patients with Alzheimer's disease and compared with those of 11 age-matched control subjects. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
When corrected for multiple comparisons, patients with visual hallucinations had significantly greater disease duration, treatment duration, motor severity and complications, sleep disturbances, in particular excessive daytime somnolence and rapid eye movement sleep behavioural disorder, disorders of mood, autonomic dysfunction and global, frontal and visuoperceptive cognitive dysfunction. 3 key findings →
Participants: 94 Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with senile dementia of the Alzheimer type frequently have difficulty performing visual tasks. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
The results indicate a pathophysiologic association between nigrostriatal dysfunction and occipital glucose metabolic reduction in PD. 3 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source
In this older population, cognitive impairment may share common age-related pathogenesis and risk factors with early AMD. 1 key finding →
Participants: 2,088 Evidence: low
Full summary, score breakdown and related studies → Original source
Most fd-OCT peripapillary RNFL and macular full-thickness and segmented inner retinal layers parameters were reduced in AD eyes compared to controls. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is the most prevalent cause of abnormal cognitive decline in older adults and commonly affects visual function. 5 key findings →
Participants: 63 Evidence: low
Full summary, score breakdown and related studies → Original source
We reviewed the polysomnograms (PSGs) of 292 consecutive patients with sleep disorders (Parkinson's disease (PD), n=19, other sleep disorders, n=273) to investigate the sensitivity and specificity of the clinical diagnosis of rapid eye movement behavior disorder (RBD) compared with polysomnographic diagnosis. 3 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Clinical accounts of Alzheimer's disease (AD) suggest that some patients exhibit markedly diminished curiosity and initiative early in the course of their illness. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
The extent of amyloid deposition within the cerebellum and the cerebral cortex was assessed and compared, using anti-amyloid protein (A4) immunostaining and a novel methenamine silver method, in 20 patients aged between 60 and 77 years with Alzheimer's disease (AD), 29 patients aged between 13 and 71 years with Down's syndrome (DS), 26 demented patients with disorders other than AD and DS and in 20 non-demented elderly individuals of age range 60-102 years. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
One of the central aims in Alzheimer's disease (AD) research is the identification of clinically relevant drug targets. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The field has made significant progress over the last 15 years. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The potential benefit of the anti-amyloid drug aducanumab based on results of recent EMERGE and ENGAGE clinical trials has generated great controversy and has very important implications for the future of anti-amyloid drug therapies. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lecanemab, a novel amyloid-sequestering agent, recently received accelerated Food and Drug Administration approval for the treatment of mild dementia due to Alzheimer disease (AD) and mild cognitive impairment (MCI). 4 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid self-assembly is linked to numerous devastating cell-degenerative diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Anti-amyloid antibody treatment for Alzheimer's disease is linked to Amyloid-Related Imaging Abnormalities (ARIA), including vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H), especially in ApoE ε4/4 carriers. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Understanding the continuum between sARIA and dARIA is crucial for improving diagnostic criteria, risk stratification, and therapeutic approaches. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
These cases suggest that recurrent ARIA-E do not inevitably lead to accelerated progression, instead, may relate to possible long-term benefits. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Drug development for Alzheimer's disease is extremely challenging, as demonstrated by the repeated failures of amyloid-β-targeted therapeutics and the controversies surrounding the amyloid-β cascade hypothesis. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid-lowering therapy via administration of monoclonal antibodies against amyloid beta has been previously associated with the formation of cerebral edema and/or microhemorrhage. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the leading cause of dementia, characterized by irreversible neuronal loss and progressive cognitive decline. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This framework is proposed as a hypothesis-generating scaffold for biomarker-informed translational studies, rather than as a validated clinical stratification system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We suggest that Aβ plaques and tau NFTs could be reinterpreted as evolutionarily conserved, compartment-specific innate immune sequestration mechanisms-an extracellular "sarcophagus" and an intracellular "lockbox"-based on their roles in microbial defense and stress response. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is undergoing a profound paradigm shift, transitioning from a localized, monolithic proteinopathy into a complex, multisystem disorder. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid related imaging abnormalities (ARIA) are the most significant risk associated with the use of anti-amyloid monoclonal antibodies (MAB) for Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events